These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
372 related items for PubMed ID: 26001561
1. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H, MOVEST Study Group. Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561 [Abstract] [Full Text] [Related]
2. Efficacy and safety of monthly ibandronate in men with low bone density. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082 [Abstract] [Full Text] [Related]
3. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S. Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148 [Abstract] [Full Text] [Related]
4. Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study. Hagino H, Ito M, Hashimoto J, Yamamoto M, Endo K, Katsumata K, Asao Y, Matsumoto R, Nakano T, Mizunuma H, Nakamura T. J Bone Miner Metab; 2018 May; 36(3):336-343. PubMed ID: 28389932 [Abstract] [Full Text] [Related]
5. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR. J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172 [Abstract] [Full Text] [Related]
6. Ibandronate: A Review in Japanese Patients with Osteoporosis. Keating GM. Drugs Aging; 2016 Apr; 33(4):295-303. PubMed ID: 26915075 [Abstract] [Full Text] [Related]
7. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H, MOVER Study Group. Calcif Tissue Int; 2013 Aug; 93(2):137-46. PubMed ID: 23644930 [Abstract] [Full Text] [Related]
13. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group. J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731 [Abstract] [Full Text] [Related]
14. Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study. Hagino H, Sakai A, Ikeda S, Imanishi Y, Tsurukami H, Nakajo S, Miyakoshi N. J Bone Miner Metab; 2019 Nov; 37(6):1013-1023. PubMed ID: 31098670 [Abstract] [Full Text] [Related]